The Pathogen Box project

Modeled after the Malaria Box, the Pathogen Box will contain ~400 diverse, drug-like molecules active against neglected diseases of interest and will be available free of charge at the end of 2015. Upon request, researchers around the world will receive a Pathogen Box of molecules to help catalyse neglected disease drug discovery. In return, researchers are asked to share any data generated in the public domain within 2 years, creating an open and collaborative forum for neglected diseases drug research.

What's happening with the Pathogen Box

The European Bioinformatics Institute’s open access database, (ChEMBL17) was analyzed and triaged to identify active chemotypes against the diseases of interest. In parallel partners from many disease areas were approached to share their expertise and contribute quality hit molecules or screening platforms. This effort has led to an initial list of 819 diverse chemotypes.

In June 2014, a Scientific Selection Committee (see below) composed of leading figures in medicinal chemistry reviewed the initial set of compounds to select 635 chemotypes termed as the “beta-set”.

These compounds are now being procured or synthesized for confirmatory screening.

Contribute to the Pathogen Box

It is not too late if you want to send us your ideas and suggestions on potential drug-like chemical scaffolds with activity against any of the pathogens to be considered for inclusion in the Pathogen Box.

All submissions will remain confidential until the launch of the Pathogen Box planned in Q4 2015. Also contributions will be acknowledged on this website.

The next review of the suggested compounds will occur in Q1 2015.

Diseases of Interest

Ascariasis, Buruli ulcer, Chagas, Cryptosporidiosis, Hookworm, Human African Trypanosomiasis, Viceral & Cutaneous Leishmaniasis, Lymphatic Filariasis, Malaria, Onchocerciasis, Schistosomiasis, Trichuriasis, Tuberculosis.


The Bill and Melinda Gates Foundation

MMV Pathogen Box Team:
Paul Wills
Benoit Laleu
Angelique Doy
Tim Wells
Dylan Pillai
Wesley van Voorhis - Former team member
Thomas Spangenberg - Former team member
Emilie Burlot - Former team member

External Contributors:
Andreas Verras, Richard T. Clark Fellowship for World Health, Merck & Co., Inc.
Joie Garfunkle, Richard T. Clark Fellowship for World Health, Merck & Co., Inc.

Selection Committee:
Simon Campbell, Chair
Charles Mowbray, DNDi
Dale Kempf, Abbvie
Gerald Shipps, TBDA
Jeremy Burrows, MMV
Leslie Street, UCT
Paul Wyatt, University of Dundee
Peter Warner, BMGF
Tom von Geldern, Independent Consultant
Lluis Ballell-Pages, GSK

Partners & Contributors To Date:
A-WOL Consortium
Barry Lab, NIAID NIH
Bickle Lab, London School of Hygiene & Tropical Medicine
Caffrey Lab, UCSF
Castellanos Lab, UTMB Galveston, Texas
Center for Discovery and Innovation in Parasitic Diseases
Guy Lab, Saint Jude Children’s Research Hospital
Huston Lab, University of Vermont
Keiser Lab, Swiss Tropical and Public Health Institute
Maes (Louis) Lab, U of Antwerp, Belgium
Nathan Lab, Weill Cornell Medical School
Northwick Park Institute for Medical Research
Pollastri Lab, Northeastern University
Sakanari Lab, UCSF
Seifert Laboratory, London School of Hygiene and Tropical Medicine
Shanmugam Lab, National Chemical Laboratory, Pune, India
Swiss TPH
Townson (Simon) Lab, Imperial College London
Tuberculosis Drug Accelerator (TBDA)
TCG Lifesciences
Ward Lab, Liverpool School of Tropical Medicine
Winzeler Lab, UCSD
Zhu Lab, Texas A&M University

                     Click chart to enlarge